KFAS
ANAB icon

Keating Financial Advisory Services’s AnaptysBio ANAB Stock Holding History

Keating Financial Advisory Services’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1
Closed -$55 – 2614
2026
Q1 		$55 Buy
+1
New +$54 ﹤0.01% 2442

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Keating Financial Advisory Services's ANAB Position: Q2 2026 in Review

Keating Financial Advisory Services sold out of AnaptysBio (ANAB) in Q2 2026, closing a stake of 1 share — an estimated $55 sold.

Keating Financial Advisory Services first reported a position in ANAB in Q1 2026 and held it in 1 quarter. The position peaked at $55 in Q1 2026. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

  • Keating Financial Advisory Services reported no remaining AnaptysBio position as of Q2 2026 after selling out during the quarter.
  • Keating Financial Advisory Services sold 1 AnaptysBio share in Q2 2026, an estimated $55.
  • Keating Financial Advisory Services first reported a position in AnaptysBio in Q1 2026 and held it in 1 quarter.
  • Keating Financial Advisory Services's AnaptysBio position peaked at $55 in Q1 2026.
  • 213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.